Recent Quotes (30 days)

You have no recent quotes
chg | %

Welichem Biotech Inc.

Find more results for WBI

Officers and directors

Liren Tang
President, Chief Executive Officer
Harvey S. K. Quan
Chief Financial Officer, Secretary
M Lyle
Vice President - Research & Development
Ryan B. Zeng
James Dai
Independent Director
Guoqing Li
Independent Director
Lai Lv
Independent Director


316-4475 Wayburne Drive
+1-604-4321703 (Phone)
+1-604-4321704 (Fax)

Website links

Welichem Biotech Inc. is a Canada-based drug discovery and early stage drug development company focusing on novel therapeutics for unmet medical needs including autoimmune and inflammatory diseases and cancers. The Company’s drug candidate, WBI-1001, was developed by the Company as a topical treatment for inflammatory skin diseases such as psoriasis and atopic dermatitis. It entered into an Asset Purchase Agreement with Stiefel, a Glaxo Group Limited company, for all the rights to the WBI-1001 technology. The Company’s other unique drug candidate, WBI-2100 and its analogous, which is in the pre-clinical stage of development, has unique dual activities of anti-cancer activity together with neutrophil boosting activity. Both WBI-1001 and WBI-2100 series compounds are derived from the metabolites of bacterial symbionts of soil living nematodes.